Intestinal inflammation
Gut-barrier and colitis research is the best-developed KPV theme.
Explore the research →INFLAMMATION & BARRIER RESEARCH
KPV
A small research peptide attracting interest around inflammation, gut health and skin support, with evidence still centred on early research.
Gut inflammationSkin barrierImmune signalling
A promising preclinical signal with a clear translation gapKPV repeatedly reduces inflammatory signals in cell and mouse models. FDA's 2026 review found no human exposure, pharmacology, efficacy or safety study for KPV by any route.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why is KPV attracting interest?
KPV attracts interest around inflammation, gut health and skin because experimental research suggests it may help calm inflammatory signalling while supporting the barriers that protect vulnerable tissue. That combination gives it an easy-to-understand appeal across both gut and skin research.
Inflammatory signalling
KPV is explored as the anti-inflammatory C-terminal fragment of alpha-MSH.
Explore the research →Skin & keratinocyte research
Topical interest follows laboratory findings in human skin-cell systems.
Explore the research →Barrier-protection potential
KPV is discussed where inflammation and epithelial damage overlap.
Explore the research →THE SCIENCE BIT
Three amino acids. An inflammation-focused idea.
KPV is the lysine–proline–valine sequence from the end of alpha-MSH. Researchers explore this small fragment for effects on inflammatory signals and epithelial barriers.
In intestinal models, the PepT1 transporter helps cells take up KPV, and experiments report changes in NF-kappaB-related signalling. A transporter is an entry route, not proof of an established treatment effect in people.
See the studies & trials →- KPV
- The three-amino-acid fragment
- PepT1
- Cellular uptake in gut models
- NF-kappaB
- Inflammatory signalling studied
How this connects to the research
Predominantly cell and animal evidence.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where KPV connects with the body
These are the tissues and biological systems behind the interest in KPV.
- Gut lining
- Epithelial uptake and inflammation.
- Skin
- Keratinocyte experiments.
- Barrier tissues
- Protection-related research.
The research behind the interest
Intestinal inflammation
Gut-barrier and colitis research is the best-developed KPV theme.
PepT1-mediated uptake studies reported reduced inflammatory signalling and disease activity in intestinal cells and multiple mouse colitis models.
Promising preclinical evidenceExplore the studies →Inflammatory signalling
KPV is explored as the anti-inflammatory C-terminal fragment of alpha-MSH.
Cell studies report effects on NF-kB-related activity and pro-inflammatory cytokine signalling across intestinal and airway epithelium.
Mechanistic evidenceExplore the studies →Skin & keratinocyte research
Topical interest follows laboratory findings in human skin-cell systems.
Keratinocyte and skin-permeation experiments provide a plausible topical research route, but they are not clinical dermatology trials.
Human cells · no treatment trialExplore the studies →Barrier-protection potential
KPV is discussed where inflammation and epithelial damage overlap.
Gut and skin models suggest a potential to protect or restore barrier tissues; whether this translates into meaningful healing in people is unknown.
Preclinical evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availablePepT1-mediated tripeptide KPV uptake reduces intestinal inflammation ↗
Human intestinal epithelial cell systems and experimental mouse colitis
Oral in mice
KPV was transported by PepT1 and reduced NF-kB activation and pro-inflammatory cytokine expression in intestinal cell systems.
Oral KPV reduced disease activity and inflammatory measures in mouse colitis; this was not a human treatment study.
KPV has anti-inflammatory potential in murine models of inflammatory bowel disease ↗
Two mouse models of intestinal inflammation
KPV treatment was associated with recovery, body-weight regain and reduced inflammatory changes in the DSS and transfer-colitis models.
The findings support a gut hypothesis but do not establish efficacy, dose or safety in people.
PepT1, KPV and colitis-associated tumorigenesis ↗
Human colorectal biopsy specimens and genetically modified mouse models
PepT1 expression was increased in human colorectal tumour specimens; KPV intervention reduced inflammation-associated tumorigenesis in PepT1-expressing mice.
The human material established transporter context only—KPV was not tested as a cancer treatment in people.
Orally targeted KPV nanoparticles in experimental ulcerative colitis ↗
Cell testing and experimental mouse colitis
Oral nanoparticle delivery in mice
Hyaluronic-acid-functionalized nanoparticles were designed to improve colonic KPV delivery and reduced inflammatory measures in mice.
The specialised formulation cannot validate ordinary oral KPV products or a human oral dose.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
FDA's 2026 review did not identify KPV products administered to humans by any route.
✓
Clinical efficacyEarly
1/5 evidence depth
No controlled human treatment trial establishes benefit for gut, skin, wound or inflammatory conditions.
◇
Safety evidenceEarly
1/5 evidence depth
Human pharmacokinetics, immunogenicity, dose-response and longer-term safety remain unknown.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Repeated cell, tissue and mouse findings support a coherent anti-inflammatory and barrier-research rationale.
HOW TO READ THESE SCORESStrong preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPE
The mechanism repeats. Human translation has not begun.
The strongest KPV case is convergence: several experiments point toward anti-inflammatory and barrier effects. The limitation is equally clear— none establishes a treatment effect or safety profile in people.
Human intestinal cell systems plus mouse colitis models.
Positive animal findings across colitis and targeted oral formulations.
Human cells and excised skin can inform mechanism, not clinical efficacy.
FDA's 2026 review found no human KPV exposure data by any route.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with KPV
People are drawn to KPV because its gut, skin and inflammatory-signalling themes fit together unusually well. The potential is worth explaining clearly, while the absence of direct human exposure data means reported benefits, preferred routes and safety assumptions remain unvalidated.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Gut comfort and more predictable days
Interest centres on abdominal discomfort, bowel symptoms and food-related disruption. People are attracted to an anti-inflammatory hypothesis, but similar symptoms can arise from very different conditions.
- What makes a report informative
- Specific symptoms, bowel pattern and everyday impact.
- What can muddy the picture
- Diet, diagnosis and other gut treatments strongly affect the comparison.
Calmer-looking, less irritated skin
Skin interest includes redness, irritation and barrier comfort. The practical goal is skin that feels and looks more settled, rather than a generic claim of reduced inflammation throughout the body.
- What makes a report informative
- Local redness, comfort and the full skincare routine.
- What can muddy the picture
- Topical formulation and moisturising effects can change the same outcomes.
A more targeted anti-inflammatory approach
The short peptide and laboratory biology attract people seeking a gentler-seeming option. That appeal is a reason for interest, not evidence that a particular route is effective or safer.
- What makes a report informative
- The exact product, route and outcome under discussion.
- What can muddy the picture
- Oral, topical and injected exposure cannot be assumed equivalent.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Gut comfort and inflammatory bowel interest
The clearest community goal is calmer gut symptoms and stronger barrier function, often in people already managing complex inflammatory conditions.
Human findings & limits
No controlled KPV treatment trial has established benefit in inflammatory bowel disease, and KPV should not replace diagnosis or proven care.
Laboratory & animal context
PepT1 transport, intestinal-cell work and multiple mouse colitis models provide a consistent positive research signal.
What this means: KPV's strongest scientific theme, with promising biology but no demonstrated human treatment effect.
Skin redness, irritation and barrier support
Topical KPV is discussed for reactive-looking skin, recovery after irritation and broader barrier support.
Human findings & limits
Human keratinocyte and skin-permeation experiments are laboratory evidence, not proof that a cream treats eczema, psoriasis or wounds.
Laboratory & animal context
Melanocortin-derived signalling and keratinocyte work provide a plausible anti-inflammatory and barrier rationale.
What this means: A credible topical research direction that still needs controlled clinical testing.
Oral versus injected KPV
People compare oral exposure for gut-focused goals with injection for broader systemic effects, even though route equivalence has never been established.
Human findings & limits
FDA's 2026 review identified no human pharmacokinetic or pharmacodynamic study by any route.
Laboratory & animal context
Mouse studies used specific oral or experimental formulations; their absorption cannot be assumed for retail capsules or injections.
What this means: Route is a major unanswered variable—not a cosmetic choice between equivalent options.
A gentler anti-inflammatory option
KPV's three-amino-acid structure and endogenous origin sometimes create an expectation of low risk or a naturally targeted effect.
Human findings & limits
No reported adverse-event cases is not the same as evidence of safety when documented human exposure is absent.
Laboratory & animal context
Models support biological activity but do not define immunogenicity, impurities, aggregation or uncommon human harms.
What this means: The short sequence is scientifically interesting, but safety still requires evidence and product-quality control.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA low-start pattern with a deliberate review point
This visual reflects a recurring published community range for oral or subcutaneous KPV. It has not been tested in a human KPV dose-finding study and is not a recommendation.
1Week 1
200 mcg · once dailyCommonly published anecdotal start
2Weeks 2–4
200–500 mcg / daySome descriptions step up within this range
3Weeks 5–8
Continue or stopCommunity course lengths vary
4After course
Pause & reviewNo evidence-based break interval
What people commonly discuss200 mcg once daily as a start, with some protocols moving toward 500 mcg daily over a four-to-eight-week course.
What remains completely unvalidatedThe dose range, step-up, duration and pause have not been linked to human KPV pharmacology, clinical efficacy or safety outcomes.
No human pharmacokinetic study defines oral absorption, exposure or an equivalent dose.
Concentration, vehicle and skin permeability vary; a topical percentage is not equivalent to a microgram injection.
No human pharmacokinetic study defines absorption, half-life, tissue exposure or dose-response.
THE MOST IMPORTANT SOURCE BOUNDARY
FDA KPV briefing document · 2026 ↗FDA's 2026 evidence review identified no clinical study or human exposure data for KPV by any route. The numerical example above is therefore labelled community-described only.
No validated human KPV dose, route, titration method or course length exists. The figures below describe a recurring community pattern—not a treatment protocol.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal / unvalidatedWhat people commonly discuss
STARTING APPROACHES
200 mcg once daily is a commonly published anecdotal starting amount for oral or subcutaneous use; topical products use formulation-specific concentrations and are not comparable.
DURATION / CYCLES
Community descriptions commonly use daily dosing for four to eight weeks, sometimes moving within a 200–500 mcg daily range.
MAINTENANCE DISCUSSION
A pause and review after a short course is often discussed, but no maintenance dose or evidence-based break interval has been validated.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial example
Community example · not clinically validatedKPV evidence is largely laboratory and animal research. It does not establish human injection amounts, this escalation or clinical benefit.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–1 | 200 mcg |
| Weeks 2–2 | 300 mcg |
| Weeks 3–3 | 400 mcg |
| Weeks 4–8 | 500 mcg |
Frequency: Every day · 1 entry per scheduled day.
This is a finite editorial example. Its ending does not establish a safe course, break or repeat cycle. No repeat is added automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with KPV
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDKPV
→
OFTEN EXPLORED WITHKPV + BPC-157
KPV + BPC-157
→
OFTEN EXPLORED WITHKPV + GHK-Cu
KPV + GHK-Cu
→
OFTEN EXPLORED WITHKPV + condition-specific care
KPV + Established treatment
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
KKPV IS USUALLY DISCUSSED AROUNDInflammatory signalling and epithelial barriers
＋Its appeal comes from a consistent preclinical story across PepT1 transport, gut inflammation and skin-cell research.
PTHE PAIRED APPROACH MAY ADDRepair biology, tissue remodelling or established care
Those roles may sound complementary, but no controlled human study shows that a KPV pairing adds benefit or remains safe.
＋
OFTEN EXPLORED WITH
Explore →＋KPV + BPC-157
KPV + BPC-157WHY IT IS EXPLOREDExplored around complementary inflammation, gut and tissue-repair narratives.
No controlled human evidence for the combination.OFTEN EXPLORED WITH
Explore →＋KPV + GHK-Cu
KPV + GHK-CuWHY IT IS EXPLOREDDiscussed in topical skin contexts combining inflammatory and remodelling themes.
Formulation and combination-specific efficacy are not established.OFTEN EXPLORED WITH
Explore →KPV + condition-specific care
KPV + Established treatmentWHY IT IS EXPLOREDThe responsible research question is whether KPV could add anything to proven gut or skin care rather than replace it.
No clinical adjunct trial establishes added benefit, interactions or an appropriate schedule.01Match the route to the question
Oral, topical and injected KPV are different exposure hypotheses—not interchangeable formats.
02Keep the component evidence separate
A finding for BPC-157, GHK-Cu or standard care does not become evidence for the combination.
03Do not replace proven treatment
Gut inflammation, persistent rash and wounds may need diagnosis and established condition-specific care.
Safety context
SAFETY & UNCERTAINTY
Interesting biology; an uncharacterised human safety profile
01ENCOURAGING CONTEXTSeveral models point in the same direction
Repeated anti-inflammatory findings across gut, airway and skin systems justify continued research into KPV's potential.
02THE HUMAN GAPNo route has a characterised safety profile
FDA found no human exposure data, clinical pharmacology or safety study for oral, topical, injected or other KPV administration.
03PRODUCT-LEVEL RISKIdentity, impurities and aggregation matter
A short peptide can still be misidentified, contaminated, degraded or aggregated; injected products add sterility and concentration risk.
What the current evidence saysFDA's 2026 review found no clinical studies or human exposure data for KPV by any route. Potential safety risks, pharmacokinetics, immune responses and longer-term effects therefore remain unknown. Oral, topical and injected exposure must not be treated as interchangeable, and product identity, impurities, aggregation and sterility can add separate risks.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Vehicle and barrier disruption can alter skin penetration, while systemic absorption has not been characterised.
Persistent bowel symptoms, bleeding, severe pain, fever, spreading rash or a non-healing wound require medical assessment.
Effects alongside anti-inflammatory, immune-modifying or other peptide products have not been adequately studied.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
14 sourcesSources used on this profile
Original publicationPepT1-mediated tripeptide KPV uptake reduces intestinal inflammationGastroenterology · full paper ↗Original publicationPepT1-mediated tripeptide KPV uptake reduces intestinal inflammationJournal / DOI ↗Bibliographic recordPepT1-mediated tripeptide KPV uptake reduces intestinal inflammationPubMed ↗Original publicationKPV has anti-inflammatory potential in murine models of inflammatory bowel diseaseJournal / DOI ↗Bibliographic recordKPV has anti-inflammatory potential in murine models of inflammatory bowel diseasePubMed ↗Original publicationPepT1, KPV and colitis-associated tumorigenesisCMGH · full paper ↗Original publicationPepT1, KPV and colitis-associated tumorigenesisJournal / DOI ↗Bibliographic recordPepT1, KPV and colitis-associated tumorigenesisPubMed ↗Original publicationOrally targeted KPV nanoparticles in experimental ulcerative colitisMolecular Therapy · full paper ↗Original publicationOrally targeted KPV nanoparticles in experimental ulcerative colitisJournal / DOI ↗Bibliographic recordOrally targeted KPV nanoparticles in experimental ulcerative colitisPubMed ↗Regulatory assessmentSafety and uncertaintyFDA 2026 KPV briefing document ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA current 503A bulk-substance status ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised KPV medicine is represented on this profile
KPV is presented as an experimental peptide. Authorised status should be checked against the MHRA products database.
MHRA products database ↗Not FDA-approved; the 503A process remained unresolved after the July 2026 advisory vote
FDA staff proposed against listing KPV because of poor characterisation and absent human effectiveness and safety data; the advisory committee later recommended inclusion. That recommendation is non-binding and does not establish drug approval, efficacy or safety.
FDA current 503A bulk-substance status ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.